[CLINICAL TRIAL OF A HYPOTENSIVE DRUG: 3,4-DIHYDROXY-D-L-PHENYLALANINE OR METHYLDOPA].
D000959:Antihypertensive Agents; D002740:Chlorothiazide; D002752:Chlorthalidone; D005132:Eye Manifestations; D006801:Humans; D006852:Hydrochlorothiazide; D006973:Hypertension; D006974:Hypertension, Malignant; D007022:Hypotension; D007024:Hypotension, Orthostatic; D008750:Methyldopa; D010649:Phenylalanine; D014116:Toxicology
D000959:Antihypertensive Agents; D006852:Hydrochlorothiazide; D010649:Phenylalanine; D008750:Methyldopa; D002740:Chlorothiazide; D002752:Chlorthalidone
CHLOROTHIAZIDE; CHLORTHALIDONE; EYE MANIFESTATIONS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTENSION, MALIGNANT; HYPOTENSION, ORTHOSTATIC; METHYLDOPA; TOXICOLOGIC REPORT
ESSAI CLINIQUE D'UNE M'EDICATION HYPOTENSIVE: L'ALPHA-M'ETHYL 3, 4-DIHYDROXYPH'ENYLALANINE OU M'ETHYLDOPA.